Does the proteasome inhibitor bortezomib sensitize to DNA-damaging therapy in gastroenteropancreatic neuroendocrine neoplasms? – A preclinical assessment in vitro and in vivo
Briest, Franziska, Koziolek, Eva J., Albrecht, Jakob, Schmidt, Fränze, Bernsen, Monique R., Haeck, Joost, Kühl, Anja A., Sedding, Dagmar, Hartung, Teresa, Exner, Samantha, Welzel, Martina, Fischer, Christian, Grötzinger, Carsten, Brenner, Winfried, Baum, Richard P., Grabowski, Patricia
Published in Neoplasia (New York, N.Y.) (01.01.2021)
Published in Neoplasia (New York, N.Y.) (01.01.2021)
Get full text
Journal Article
Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer
Frank, Katrin J., Mulero-Sánchez, Antonio, Berninger, Alexandra, Ruiz-Cañas, Laura, Bosma, Astrid, Görgülü, Kıvanç, Wu, Nan, Diakopoulos, Kalliope N., Kaya-Aksoy, Ezgi, Ruess, Dietrich A., Kabacaoğlu, Derya, Schmidt, Fränze, Kohlmann, Larissa, van Tellingen, Olaf, Thijssen, Bram, van de Ven, Marieke, Proost, Natalie, Kossatz, Susanne, Weber, Wolfgang A., Sainz, Bruno, Bernards, Rene, Algül, Hana, Lesina, Marina, Mainardi, Sara
Published in Cell reports. Medicine (15.11.2022)
Published in Cell reports. Medicine (15.11.2022)
Get full text
Journal Article